Suppression of Corneal Neovascularization With Cyclosporine

Effects of topical 2% cyclosporine A on the corneas of dogs subjected to lamellar keratoplasty with a graft of equine pericardium preserved in glycerin: clinical and morphological evaluation

“…It was successfully used in topic treatment, decreasing the neovascularization in the cornea of dogs presenting keratoconjunctivitis sicca (KASWAN et al, 1989). It also reduced corneal vascularization that developed in mice after an intracorneal injection of interleukin-2, when intramuscularly administered (LIPMAN et al, 1992). Ciclosporine A given subcutaneously also has been found to supress new vessel formation induced in the mesenteric-window assay in rats (NORRBY, 1992).…”

“…On the other hand, it is not desirable due to the loss of corneal transparency (PEIFFER JR. et al, 1999). Several trials have been performed in order to evaluate aspects related to corneal vascularization (SUNDERKOTTTER et al, 1991a;REHANY & WAISMAN, 1994;KENYON et al, 1996;BENELLI et al, 1997;BARROS et al, 2000) and several therapeutic schemes were attempted in order to decrease or inhibit it, mainly the topic or systemic administration of cyclosporine A at different concentrations (LIPMAN et al, 1992;REHANY & WAISMAN, 1994;BENELLI et al, 1997).…”

“…The present trial was performed in order to evaluate the lamellar keratoplasty with an equine pericardial graft preserved in glycerin and the effects of topic cyclosporine A on these corneas of dogs, because it does not interfere in the cicatricial process of the cornea (READ, 1996); because of its potential for decreasing corneal vascularization (EPSTEIN et al, 1987;LIPMAN et al, 1992;NORRBY, 1992;BENELLI et al, 1997) and because of the beneficial results observed using topical cyclosporine A on several corneal inflammatory affections (KASWAN et al, 1989;JACKSON et al, 1991;MORGAN & ABRAMS, 1991;READ, 1996;STEVENSON et al, 2000).…”

The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF

“…A variety of angiogenic factors can stimulate angiogenesis in vitro and vivo. This includes angiogenin (Fett et al, 1985;Bond and Vallee, 1988;Risau, 1990), basic fibroblastic growth factor (bFGF) (Adamis et al, 1991), vascular endothelial growth factor (VEGF) (Amano et al, 1998), prostaglandins (Ziche et al, 1982), interleukin 2 and 8 (Koch et al, 1992;Lipman et al, 1992), and platelet derived endothelial cell growth factor (PD-ECGF) (Risau, 1990). And also a number of antiangiogenic molecules have been identified (Folkman et al, 1995).…”

“…Corneal neovascularization is also thought to predispose to the rejection of corneal allograft by facilitating the exposure of antigens to the host immune system (Hill and Maske, 1988). The mechanism of corneal neovascularization has been extensively investigated, in lieu of various mediators such as basic fibroblastic growth factor (bFGF) (Adamis et al, 1991), vascular endothelial growth factor (VEGF) (Amano et al, 1998), prostaglandins (Ziche et al, 1982), interleukin 2 and 8 (Koch et al, 1992;Lipman et al, 1992), and platelet derived endothelial cell growth factor (PD-ECGF) (Risau, 1990). Recently, a number of antiangiogenic molecules in the physiological system have been identified (Folkman, 1995).…”